New biologics in the management of Crohn’s disease: focus on certolizumab pegol

References

• StangeEFTravisSPVermiereSEuropean evidence based consensus on the diagnosis and management of Crohn’s disease: definitions and diagnosisGut200655Suppl 1i11516481628
   PubMed Web of Science ®Google Scholar
• SchwartzDALoftusEVJrTremaineWJThe natural history of fistulzing Crohn’s disease in Olmsted Country. MinnesotaGastroenterology2002122487588011910338
   PubMed Web of Science ®Google Scholar
• LoftusEVClinical epidemiology of inflammatory bowel disease: incidence, prevalence and environmental influencesGastroenterology200412661504151715168363
   PubMed Web of Science ®Google Scholar
• LoftusEVJrSchoenfeldPSandbornWJThe epidemiology and natural history of Crohn’s disease in population-based patient cohorts from North America: a systematic reviewAliment Pharmacol Ther2002161516011856078
   PubMed Web of Science ®Google Scholar
• LoftusEVJrSandbornWJEpidemiology of inflammatory bowel diseaseGastroenterol Clin North Am200231112012122726
   PubMed Web of Science ®Google Scholar
• XavierRJPodolskyDKUnrevealing the pathogenesis of inflammatory bowel diseaseNature200744842743417653185
   PubMed Web of Science ®Google Scholar
• RussellRKSatsangiJIBD: a family affairBest Pract Res Clin Gastroenterol20041852553915157825
   PubMed Web of Science ®Google Scholar
• HugotJPChamaillardMZoualiHAssociation of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s diseaseNature200141159960311385576
   PubMed Web of Science ®Google Scholar
• ChoJHWeaverCTThe genetics of inflammatory bowel diseaseGastroenterology20071331327133917919503
   PubMed Web of Science ®Google Scholar
• RosenstielPHuseKTillAA short isoform of NOD2/CARD15, NOD2-s, is an endogenous inhibitor of NOD2 receptor-interacting protein kinas 2-induced signalling pathwaysProc Natl Acad Sci U S A20061033280328516492792
   PubMed Web of Science ®Google Scholar
• RiouxJDDalyMJSilverbergMSGenetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn’s diseaseNat Genet200129222322811586304
   PubMed Web of Science ®Google Scholar
• DuerrRHTaylorKDBrantSRA genome-wide association study identifies IL23R as an inflammatory bowel disease geneScience20063141461146317068223
   PubMed Web of Science ®Google Scholar
• PeltekovaVDWintleRFRubinLAFunctional variation of OCTN cation transporter genes are associated with Crohn’s diseaseNat Genet20043647147515107849
   PubMed Web of Science ®Google Scholar
• EconomouMTrikalinosTALoizouKTDifferential effects of NOD2 variants on Crohn’s disease risk and phenotype in diverse populations: a metaanalysisAm J Gastroenterol2004992393240415571588
   PubMed Web of Science ®Google Scholar
• BrantSRPiccoMFAchkarJPDefining complex contributions of NOD2CARD15 gene mutations, age, at onset, and tobacco use on Crohn’s disease phenotypesInflamm Bowel Dis2003928128914555911
   PubMed Web of Science ®Google Scholar
• Alvarez-LobosMArosteguiJISansMCrohn’s disease patients carrying Nod2/CARD15 gene variants have an increate and early need for first surgery due to structuring disease and higher rate of surgical recurrenceAnn Surg200524269370016244543
   PubMed Web of Science ®Google Scholar
• MathewCGNew links to the pathogenesis of Crohn’s disease provided by genome-wide association scansNat Rev Genet2008991417968351
   PubMed Web of Science ®Google Scholar
• BarrettJCHansoulSNicolaeDLGenome-wide association defines more than 30 distinct susceptibility loci for Crohn’s diseaseNat Genet20084095596218587394
   PubMed Web of Science ®Google Scholar
• ArmotageELAldhoursMCAndersonNIncidence of juvenile-onset Crohn’s disease in Scotland: association with northern latitude and affluenceGastroenterology200412741051105715480983
   PubMed Web of Science ®Google Scholar
• CosnesJBeagugerieLCarbonnelFSmoking cessation and the course of Crohn’s disease: an intervention studyGastroenterology200112051093109911266373
   PubMed Web of Science ®Google Scholar
• Sanchez-MuñozFDominguez-LopezAYamamoto-FurushoJKRole of cytokines in inflammatory bowel diseaseWorld Gastroenterol2008142742804288
   PubMed Web of Science ®Google Scholar
• ArseneauKOTamagawaHPizarroTTInnate and adaptive immune responses related to IBD pathogenesisCurr Gastroenterol Rep20079650851218377804
   PubMedGoogle Scholar
• CominelliFCytokine based therapies for Crohn’s disease. New paradigmsN Engl J Med20043512045204815537904
   PubMed Web of Science ®Google Scholar
• SuCLinchesteinGRKrokKA meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn’s diseaseGastroenterology20041261257126915131785
   PubMed Web of Science ®Google Scholar
• TravisSPStangeEFLèmannMEuropean evidence based consensus on the diagnosis and management of Crohn’s disease: current managementGut200655Suppl Ii16i3516481629
   PubMed Web of Science ®Google Scholar
• ReineckerHCSteffenMWitthoeftTEnhanced secretion of tumor necrosis factor alfa, IL6, and IL1-beta by isolated lamina propria mononuclear cells from patients with ulcerative and Crohn’s colitisClin Exp Immunol1993941741818403503
   PubMed Web of Science ®Google Scholar
• MurchSHLamkinVASavageMOSerum concentrations of tumor necrosis factor alpha in childhood chronic inflammatory bowel diseaseGut1991329139171885073
   PubMed Web of Science ®Google Scholar
• BraeggerCPNichollsSMurchSHTumor necrosis alpha in stool as marker of intestinal inflammationLancet199233989911345871
   PubMed Web of Science ®Google Scholar
• BeartFNomanMVermiereSInfluence of immunogenicity on long-term efficacy of infliximab in Crohn’s diseaseN Engl J Med200334860160812584368
   PubMed Web of Science ®Google Scholar
• LangLFDA approves Cimzia to treat Crohn’s diseaseGastroenterology2008134181918474249
   PubMed Web of Science ®Google Scholar
• LugeringASchmidtMLugeringNInfliximab induces apoptosis in monocytes from patients with chronic active Crohn’s disease by using a caspase-dependent pathwayGastroenterology20011211145115711677207
   PubMed Web of Science ®Google Scholar
• ShenCAsscheGVColpaertSAdalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanerceptAliment Pharmacol Ther20052125125815691299
   PubMed Web of Science ®Google Scholar
• Van den BrandeJMBraatHvan den BrinkGRInfliximab but not etanercept induced apoptosis in lamina propria T-lymphocytes from patients with Crohn’s diseaseGastroenterology 2031241774178512806611
   PubMed Web of Science ®Google Scholar
• Ten HoveTvan MontfransCPeppelenboschMPinfliximab treatment induces apoptosis of lamina propria T-lymphocyte in Crohn’s diseaseGut20025020621111788561
   PubMed Web of Science ®Google Scholar
• ScallonBJMooreMATrinhHChimeric anti-TNFα monoclonal antibody cA2 binds recombinant trans membrane TNFα and activate immune effector functionsCytokine199572512597640345
   PubMed Web of Science ®Google Scholar
• KirchnerSHollerEHaffnerSEffect of different tumor necrosis factor (TNF) reactive agents on reverse signaling of membrane integrated TNF in monocytesCytokine200428677415381183
   PubMed Web of Science ®Google Scholar
• NesbittAFossatiGBerginMMechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor α agentsInflamm Bowel Dis2007131323133217636564
   PubMed Web of Science ®Google Scholar
• FossatiGNesbittAMIn vitro complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by the anti-TNF agents adalimumab, etanercept, infliximab, and certolizumab pegol (CDP870)Am J Gastroenterol2005100Suppl 9S299
   Web of Science ®Google Scholar
• NesbittAMHenryAJHigh affinity and potency of the pegylated fab′ fragment CDP870. Direct comparison with other anti-TNF agentsAm J Gastroenterol200499Suppl 10S253
   Web of Science ®Google Scholar
• ShaoLMChenMYChenQYSystematic review: the efficacy and safety of certolizumab pegol in Crohn’s diseaseAliment Pharmacol Ther20092960561419183161
   PubMed Web of Science ®Google Scholar
• WinterTAWrightJGhoshSIntravenous CDP870, a PEGylated Fa’ fragment of humanized antitumor necrosis factor antibody, in patients with moderate to severe Crohn’s disease: an exploratory studyAliment Pharmacol Ther2004201337134615606396
   PubMed Web of Science ®Google Scholar
• SchreiberSRutgeertsPFedorakRA randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn’s diseaseGastroenterology200512980781816143120
   PubMed Web of Science ®Google Scholar
• FaganEADyckRFMatonPNSerum levels of C-reactive protein in Crohn’s disease and ulcerative colitisEur J Clin Invest1982123513596814926
   PubMed Web of Science ®Google Scholar
• SandbornWJFeganBGStoinovSCertolizumab pegol for the treatment of Crohn’s diseaseN Engl J Med200735722823817634458
   PubMed Web of Science ®Google Scholar
• SchreiberSKhaliqkareemiMLawranceICMaintenance therapy with certolizumab pegol for Crohn’s diseaseN Engl J Med200735723925017634459
   PubMed Web of Science ®Google Scholar
• SchreiberSHanauerSBFeaganGLong-term treatment with certolizumab pegol for up to 18 month in patients with active Crohn’s disease: PRECISE 3efficacy resultsGastroenterology2007132A504
   Web of Science ®Google Scholar
• SandbornWJHanauerSBRutgeertsPJRe-induction and maintenance therapy with subcutaneous certolizumab pegol in patients with Crohn’s disease following treatment failure: PRECISE4 resultsGastroenterology2007132A505
   Web of Science ®Google Scholar
• RutgeertsPFeaganBGLichensteinGRComparison of scheduled and episodic treatment strategies of infliximab in Crohn’s diseaseGastroenterology200412640241314762776
   PubMed Web of Science ®Google Scholar
• VermiereSAbrreuMYD’HaensGEfficacy and safety of certolizumab pegol in patients with active Crohn’s disease who previously lost response ore were intolerant to infliximab: open label induction preliminary results of the WELCOME studyGastroenterology2008134A67
   Web of Science ®Google Scholar
• DaneseSMocciaroFGuidiLSuccessful induction of clinical response and remission with certolizumab pegol in Crohn’s disease refractory or intolerant to infliximab: a real-life multicenter experience of compassionate useInflamm Bowel Dis2008141168117018357580
   PubMed Web of Science ®Google Scholar
• ColombelJFSandbornWJRutgeertsPAdalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: CHARM trialGastroenterology2007132526517241859
   PubMed Web of Science ®Google Scholar
• TraceyDKlareskorgLSassoEHTumor necrosis factor antagonist mechanisms of action: a comprensive reviewPharmacol Ther200811724427918155297
   PubMed Web of Science ®Google Scholar
• D’HaensGBaertFvan AsscheGEarly combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trialLancet200837166066718295023
   PubMed Web of Science ®Google Scholar
• SandbornWRutgeertsPReinishchWSONIC: a randomized, double blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn’s disease naïve to immunomodulators and biologic therapyAm J Gastroenterol20081031117
   Web of Science ®Google Scholar
• LichtensteinGRColombelJFBloomfieldRLong-term safety of an anti-TNF drug by duration of exposure compared to non anti-TNF exposed patiens with Crohn’s disease: novel data from the certolizumab pegol development programGastroenterology20081343A68
   Google Scholar
• HanauerSBFeaganBGLichtensteinGRMaintenance infliximab for Crohn’s disease: the ACCENT I randomized trialLancet20023591541154912047962
   PubMed Web of Science ®Google Scholar
• GuyattGHMitchellAIrvineEJA new measure of health status for clinical trials in inflammatory bowel diseaseGastroenterology1989968048102644154
   PubMed Web of Science ®Google Scholar
• IrvineEJFeaganBRochonJQuality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel diseaseGastroenterology19941062872968299896
   PubMed Web of Science ®Google Scholar